Roche

Jul 30, 2020

Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal's total near to USD 2 billion. Th...

Jul 14, 2020

Merck Collaborates with Dewpoint Therapeutics to Cure HIV with Condensates   Merck has forged a collaboration with Boston-based Dewpoint Therapeutics to treat HIV using Dewpoint’s proprietary platform for condensate-based drug discovery.Under the terms of the agreement, Dewpoint is eligible for receiving ...

Jul 01, 2020

Over the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer, and in 2018 was estimated to be responsible for 9.6 million deaths. Costing people quality of lives and eventually lea...

Jun 30, 2020

Intercept Pharmaceuticals receives a clear rejection from the FDA for its NASH drug, Obeticholic acid (OCA) Intercept Pharmaceuticals announced the issuance of a Complete Response Letter (CRL) by the FDA regarding the New Drug Application (NDA) for Obeticholic acid (OCA) for the treatment of fibrosis due to ...

Jun 11, 2020

AbbVie Seals a USD 750 M Bispecific Antibody Cancer Drug Deal with Genmab   AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement features up to USD 3.2 billion in milestones, positions AbbVie to race Reg...

Jun 05, 2020

Prostate Cancer Market Size is Expected to Increase with a CAGR of 8.1% in the 7MM for the study period of 2017-30 owing to rich Pipeline, Increasing Awareness and Better Treatment Options. A malignancy of prostate glands, Prostate Cancer, develops slowly and remains confined to prostate glands, however, can inv...

May 12, 2020

MyoKardia has announced the promising results of Phase III clinical trials of its lead drug mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Following the announcement, shares of the California-based company skyrocketed. The Phase III clinical trial - EXPLORER-HCM – demonstrated the pot...

May 11, 2020

Several promising new developments and novel treatment approaches are fuelling Huntington’s disease Market. Progressive neurological disorders such as Parkinson disease (PD), motor neuron disease (MND), Huntington disease (HD), or multiple sclerosis (MS), despite the advent of technological advances in healthc...

May 05, 2020

Florence-based Menarini Group has announced a USD667 million acquisition of the Stemline Therapeutics, an oncology-focused company. As per the agreement, Menarini plans to help Stemline to build a strong foothold in the U.S., and will also continue the development of Elzonris, a CD123 targeted therapy. Th...

Apr 09, 2020

AstraZeneca aims for summer start for COVID-19 antibody trial AstraZeneca has made its multipronged approach to the development of antibodies against the pandemic SARS-CoV-2 virus. The giant is utilizing its discovery capabilities and assisting in assessing the candidates who were identified in China and the U.S...